- $489.43m
- $601.01m
- $297.18m
Evolus Inc reports results for the quarter ended in June - Earnings Summary
Brief: Evolus Q2 Net Income USD -18.14 Million
Evolus Inc expected to post a loss of 19 cents a share - Earnings Preview
Evolus hits over two-month high, raises 2023 revenue outlook
Brief: Evolus Launches Nuceiva In Italy
Brief: Evolus Announces Successful Completion Of Phase 2 Study Evaluating “Extra-Strength” Dose Of Jeuveau
Brief: Evolus Files For Offering Of Up To $50 Mln Shares Of Common Stock
U.S. RESEARCH ROUNDUP-Integral Ad Science Holding, Paratek Pharmaceuticals, Veru
Evolus surges on partnership with French firm for dermal fillers
Evolus Inc reports results for the quarter ended in March - Earnings Summary
Brief: Evolus Sees FY sales USD 180-190 million
Brief: Evolus Reports First Quarter 2023 Results And Provides Business Update
Brief: Evolus Expands Into U.S. Dermal Filler Market With Evolysse
Evolus Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Evolus Holds No Deposits At SVB Or Signature Or Any Direct Investments At SVB Or Signature
Brief: Evolus Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing
Brief: Evolus Reports Fourth Quarter And Full Year 2022 Results And Provides Business Update
Brief: Evolus Expects FY sales USD 180-190 million
Evolus Inc expected to post a loss of 15 cents a share - Earnings Preview